Stock Price & Analysis

Based on the recent data and market analysis, here's a concise assessment of AMGN stock:

Technical Analysis

The stock is currently trading at $272.11, showing a moderate upward momentum with RSI at 54.38, indicating a neutral position. The stock is trading above its 20-day moving average of $263.65, suggesting short-term bullish sentiment.

Recent Catalysts

1. FDA Approval: Amgen received FDA approval for Lumakras plus Vectibix combination therapy for treating KRAS G12C-mutated metastatic colorectal cancer. This approval represents a significant advancement in their oncology portfolio.

2. Medicare Price Negotiations: Amgen's psoriasis drug Otezla has been selected for Medicare price negotiations, which could impact future revenue streams. However, the new prices won't take effect until 2027, giving the company time to adjust strategies.

Analyst Sentiment

Recent analyst actions show mixed sentiment:

• Wells Fargo maintained Hold rating with PT $280 (7.12% upside)
• Piper Sandler maintains Buy rating with PT $310 (19.55% upside)
• B of A Securities has an Underperform rating with PT $256 (-7.47% downside)

Conclusion SELL recommendation at current levels based on:

1. Mixed analyst sentiment with concerns about patent expiries
2. Upcoming Medicare price negotiations creating revenue uncertainty
3. Technical indicators showing neutral momentum
4. Current price near analyst consensus targets, limiting upside potential

Based on the provided data and references, here's the price prediction for AMGN stock in 2025:

AMGN's stock price is projected to reach $349 by end of 2025, representing a 28% upside from current levels of $272.11, driven by strong performance in its core drug portfolio and promising developments in weight loss treatment MariTide. The company's recent FDA approval for Lumakras plus Vectibix combination therapy for colorectal cancer treatment demonstrates continued innovation and market expansion. Despite Medicare price negotiation pressures on Otezla starting 2027, Amgen's diverse product portfolio and robust pipeline support sustained growth.

The S1 support level for AMGN Stock is $263.24 ,The R1 resistant level for AMGN Stock is $276.57.

As of the end of day on 2025-01-24, the price of AMGN Stock was $277.

The target price for AMGN Stock according to analyst rating is 334.76, with the highest price target at 405.00 and the lowest at 256.00. Analysts have a Moderate Buy rating on AMGN Stock overall.

The market cap of AMGN is $148.0B.

Based on the provided data and current valuation metrics, here's a concise analysis of AMGN's valuation:

Valuation Analysis: AMGN currently trades at a P/E ratio of 41.17 (Q3 2024), which is significantly higher than its historical average. The EV/EBITDA ratio stands at 19.03, indicating a premium valuation compared to industry standards.

Technical Indicators: The stock's RSI of 54.38 suggests neutral momentum, while the negative MACD (-2.06) indicates some bearish pressure. The price is currently trading above its 20-day moving average of $263.65, showing short-term strength.

Analyst Consensus: Recent analyst actions suggest mixed sentiment. Wells Fargo maintained a Hold rating with a price target of $280, while Truist Securities lowered their target to $298, citing uncertainty in the macro environment and few near-term catalysts.

Key Overvaluation Factors:

1. Trading at premium multiples compared to historical averages
2. Price-to-Sales ratio of 5.34 indicates expensive valuation
3. Limited near-term growth catalysts as noted by analysts
4. High P/B ratio of 23.01 suggests significant premium to book value

Recent Developments: The FDA approval of Lumakras plus Vectibix combination therapy provides some positive momentum, but this appears to be already priced into the current valuation.

Based on these factors, AMGN appears to be overvalued at current levels, with limited upside potential given the premium valuation multiples and mixed growth outlook.

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others.

Based on the available data and market analysis, here's the 2030 price prediction for AMGN stock in three concise sentences:

AMGN stock is projected to reach $425-450 by 2030, driven by its strong pipeline including recent FDA approvals like Lumakras plus Vectibix combination therapy and continued dominance in biotechnology-based therapeutics. The company's robust financial health with a current PE ratio of 41.17 and consistent revenue growth of 23.18% suggests sustained long-term growth potential, despite potential headwinds from Medicare price negotiations affecting some of its products [3,5]. Technical analysis shows AMGN maintaining an upward trajectory with strong support levels, while its strategic acquisitions like Horizon and growing biosimilar portfolio position it well for future market expansion.

AMGN has a total of 26700 employees.